Sgd Pharma

SGD Pharma, a French-headquartered company in the Rubber and Plastic Products industry, has reported its carbon emissions and established climate commitments.

In 2025, SGD Pharma's reported Scope 1 emissions were approximately 124,953,000 kg CO2e, Scope 2 market-based emissions were about 33,784,000 kg CO2e, and Scope 3 emissions totalled roughly 318,760,000 kg CO2e. Looking back to 2024, the company's Scope 1 emissions were around 121,554,000 kg CO2e, Scope 2 market-based emissions were about 59,909,000 kg CO2e, and Scope 3 emissions were approximately 328,933,000 kg CO2e. For 2023, Scope 1 emissions were roughly 138,080,000 kg CO2e, Scope 2 market-based emissions were about 61,596,000 kg CO2e, and Scope 3 emissions were approximately 320,289,000 kg CO2e. In 2022, Scope 1 emissions stood at approximately 142,402,000 kg CO2e, Scope 2 market-based emissions at about 76,332,000 kg CO2e, and Scope 3 emissions at roughly 319,467,000 kg CO2e. In 2021, the company disclosed Scope 1 emissions of approximately 131,100,000 kg CO2e and Scope 2 market-based emissions of about 67,569,000 kg CO2e.

SGD Pharma is committed to achieving climate neutrality by 2050. The company aims to reduce its Scope 1 and Scope 2 CO2 emissions by 35% by 2030, compared to a 2020 baseline, across its plants in France, Germany, India, and China. Furthermore, a long-term target is in place to cut Scope 1 and Scope 2 emissions by 65% by 2040, also against a 2020 baseline. More specifically, SGD Pharma has committed to reducing its Scope 1 and 2 CO2 emissions by 42% by 2030, referencing 2022 levels, to align with the 1.5°C climate threshold. The company has also set a long-term target of a 65% reduction in overall CO2 emissions by 2040, with a baseline year of 2023. SGD Pharma is committed to setting Science Based Targets, as indicated by its "Committed" status for near-term targets with the Science Based Targets initiative (SBTi).